サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：3Dバイオプリンティングの世界市場-2023年～2030年
市場調査レポート
商品コード
1345380

3Dバイオプリンティングの世界市場-2023年～2030年

Global 3D Bioprinting Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
3Dバイオプリンティングの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の3Dバイオプリンティング市場は、2022年に20億米ドルに達し、2023-2030年の予測期間中にCAGR 16.1％で成長し、2030年には64億米ドルに達すると予測されています。

3Dバイオプリンティングとして知られる積層造形法では、生きた細胞や栄養素を有機成分や生物学的成分と結合させ、天然のヒト組織に似た合成構造を作り出します。組織工学、生物工学、材料科学の各分野はすべて、さまざまな生物学的応用のために3Dバイオプリンティングの恩恵を受けることができます。さらに、この技術は医薬品の研究や承認にもますます利用されるようになっています。バイオプリンティング研究の現在の焦点は、3Dプリント皮膚や骨移植片、インプラント、さらには完全な3Dプリント臓器などの臨床応用です。

さらに、政府のイニシアティブやインセンティブプログラムの採用の増加、美容治療や進歩における3Dバイオプリンターの使用の増加、動物実験を減らすのに役立つ臨床研究や薬物スクリーニングにおける3Dバイオプリンティングの使用などの要因が、3Dバイオプリンティング市場規模の成長を促進しています。米国やカナダのような国々での技術進歩の大規模な上昇により、市場は北米地域からの需要の増加を経験しています。

市場力学

市場成長を促進する企業の戦略

製品上市、製品承認、提携、買収などの戦略は、市場の成長を促進するのに役立ちます。例えば、2021年3月、バイオコンバージェンスで世界をリードするCELLINK社によって、生体適合医療機器の作成を含むバイオメディカル生産のための高スループットバイオファブリケーションと精密な3Dバイオプリンティングのために作成された最新世代のバイオプリンターであるBIO MDXシリーズが発表されました。

3Dバイオプリンティングが組織工学、細胞培養、再生医療の分野で研究者が選択する技術として人気が高まるにつれ、過去5年間、バイオファブリケーション技術全体でより優れた自動化、精度、再現性に対するニーズが高まってきました。

さらに、2022年11月22日には、インドの技術系スタートアップ企業であるAvay Biosciences社が、同社によればヒト組織を製造できる国産の3Dプリンターを発表しました。インド科学研究所では、「Mito Plus」バイオプリンターの最初のプロトタイプが設置されました。洗練されたバイオ3Dプリンター「Mito Plus」は、IITマドラスの卒業生が共同設立したAvay社が、IIScの研究室からプロトタイプへのフィードバックを得て作成しました。このように、新製品発売の増加は市場拡大に寄与しています。

治療における技術進歩

近年、3Dバイオプリンティングの目的は大きく進歩し、人への移植に成功する臓器をプリントすることが可能になっています。実現はまだ先のこととはいえ、この技術は現在も研究開発中であり、研究開発が進めば、脳腫瘍、パーキンソン病、アルツハイマー病、脊髄損傷など、さまざまな病気に対する新たな優れた治療法が生まれる可能性があります。

通常の3Dプリンティング技術を少し変更するだけで、生きた細胞を3Dで作成することができます。CADファイルに従って、プリンターが材料を連続的に積層し、形状を作成します。バイオインクとは、バイオプリンターが金属やポリマーの代わりに使用する材料です。これらはアルギン酸やゼラチンのような粘性のある物質でできており、生きた細胞を含んでいます。足場は、細胞が作られる間、細胞を支え保護するために頻繁に使用されます。3Dバイオプリンティング・ビジネスは、最近の多くの進歩の結果として拡大しています。

例えば、米国技術者協会によると、新しい発明は、大きな火傷の傷を覆うために生体材料の皮膚のシートを堆積させるポータブル3Dプリンタです。さらに、この生体材料は治癒を早める。この技術は、トロントのサニーブルック病院とトロント大学の研究者が開発したもので、バイオインクを火傷の傷口に帯状に塗布します。間葉系間質細胞（MSCs）は、環境に応じて複数の細胞型に発達することができる幹細胞であり、バイオマテリアルを作るために使用されます。このように、技術の成長が市場拡大に寄与しています。

高額な治療費

この高度な技術を使えば、患者が一刻も早く臓器移植を受けられるようになると多くの人が考えているにもかかわらず、手術費用は決して安くはありません。技術が進歩すればするほど、何をするにも費用がかかります。臓器のバイオプリントに必要な材料のコストも上昇しています。

生体組織の作製には1,000ドルもかかりませんが、3D臓器プリントに使われるバイオプリンターの大半は10万米ドルもします。臓器プリントが高価なのは、必要な研究を行うのに多くの時間がかかることと、プロセスが効果的であることを確認するために高度な資格を持ち経験豊富な作業員が必要なためです。そのため、臓器にかかる費用が高額になり、市場の成長が制限されることになります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 各社の戦略
      • 治療における技術的進歩
    • 抑制要因
      • 治療費の高さ
    • 機会
      • 臓器移植の需要増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • 疫学統計
  • パイプライン分析
  • 特許分析
  • 技術動向
  • ロシア・ウクライナ戦争の影響分析
  • SWOT分析

第6章 COVID-19分析

第7章 コンポーネント別

  • 3Dバイオプリンター
    • 医療用ベッド
    • 浴室・トイレ補助機器
    • 読書・筆記・計算補助器具
  • バイオインク

第8章 技術別

  • 押出ベース・バイオプリンティング
  • インクジェットベース・バイオプリンティング
  • 圧力支援バイオプリンティング
  • レーザー支援バイオプリンティング
  • その他

第9章 用途別

  • 医療
    • 組織・臓器生成
    • 医療用錠剤
    • 補綴物・インプラント
    • その他
  • 歯科
  • バイオセンサー
  • 消費者/個人向け製品検査
  • その他

第10章 エンドユーザー別

  • 病院
  • 研究機関・学術機関
  • バイオ医薬品企業

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Organovo Holdings Inc
    • 企業概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な動向
  • UPM Biomedicals
  • GE Healthcare
  • Regemat 3D
  • 3DSMAN
  • CELLINK
  • Aspect Biosystem
  • Formlabs
  • Avay Biosciences
  • Precise Bio.

第14章 付録

目次
Product Code: BT6751

Market Overview

Global 3D Bioprinting Market reached US$ 2.0 billion in 2022 and is expected to reach US$ 6.4 billion by 2030 growing with a CAGR of 16.1% during the forecast period 2023-2030.

In the additive manufacturing method known as 3D bioprinting, living cells and nutrients are joined with organic and biological components to produce synthetic structures that resemble natural human tissues. The branches of tissue engineering, bioengineering, and materials science can all benefit from 3D bioprinting for a variety of biological applications. Additionally, the technology is increasingly being used for drug research and approval. The present focus of bioprinting research is on clinical applications including 3D printed skin and bone grafts, implants, and even complete 3D printed organs.

Additionally, factors such as the rising adoption of government initiatives, and incentive programs, the rising use of 3D bioprinters in beauty treatments and advancements, the use of 3D bioprinting in clinical studies and drug screening which helps to reduce animal testing, are driving the growth of the 3D Bioprinting market size. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experincing an rise in demand from North American regions.

Market Dynamics

The Strategies Followed by the Companies Helps to Drive the Market Growth

The strategies like product launches, product approvals, partnerships and acquisitions helps to drive the market growth. For instance, in March 2021, the BIO MDX Series, the most recent generation of bioprinters created for high-throughput biofabrication and precise 3D bioprinting for biomedical production, including the creation of biocompatible medical equipment, has been introduced by CELLINK, the leading bioconvergence firm in the world.

There has been a larger need for better automation, precision, and repeatability across biofabrication techniques over the past five years as 3D bioprinting has grown in popularity as the technique of choice for researchers working in the fields of tissue engineering, cell culture, and regenerative medicine.

Additionally, on November 22, 2022, an Indian tech start-up called Avay Biosciences has unveiled a homegrown 3D printer that, according to the company, can manufacture human tissues. At the Indian Institute of Science, the 'Mito Plus' bioprinter's first prototype was installed. The sophisticated Bio 3D printer Mito Plus was created by Avay, which was co-founded by an IIT Madras alumnus, with feedback on the prototype from the research lab at IISc. Thus, an increase in new product launches contributes to market expansion.

Technological Advancements in the Treatment

The objective of 3D bioprinting has advanced significantly in recent years, and it is now possible to print organs that can be successfully transplanted into people. Even while that is still a long way off, the technique is still being researched and developed, and advancements could result in new and better therapies for ailments including brain cancer, Parkinson's disease, Alzheimer's disease, and spinal cord injury, among many others.

With a few modifications, normal 3D printing techniques are used to create living cells in 3D. In accordance with a CAD file, the printer applies material in successive layers to create a shape. Bioinks are the materials used by bioprinters instead of metals or polymers. These are made of viscous substances like alginate or gelatin and contain living cells. Scaffolding is frequently used to support and safeguard the cells while they are created. The 3D bioprinting business is expanding as a result of many recent advancements.

For instance, according to American Society of Mechnical Engineers, new invention is a portable 3D printer that deposits sheets of biomaterial skin to cover big burn wounds. Additionally, the biomaterial speeds up the healing process. The technology, developed by researchers at Sunnybrook Hospital and the University of Toronto in Toronto, applies bio ink to burn wounds strip by strip. The mesenchymal stroma cells (MSCs), stem cells that can develop into multiple cell types depending on their environment, are used to make the biomaterial. Thus, the growth of technology contributes to market expansion.

High cost of Treatment

Even though many people believe that using this advanced technology will allow patients to have an organ transplant as soon as possible, the operation is not affordable. The cost of having anything done increases as technology advances. The cost of the materials required for bioprinting organs has also increased.

While producing living tissues can cost as little as $1,000, the majority of bioprinters used for 3D organ printing can cost as much as $100,000. Organ printing is expensive due to the fact that it takes a lot of time to do the needed research and because it needs highly qualified and experienced workers to make sure the process is effective. Thus due to expensive cost of organs will restrict the market growth.

Segment Analysis

The global 3D bioprinting market is segmented based on component, technology, application, end user and region.

The Hospitals Accounted for Approximately 31.07% of the 3D Bioprinting Market Share

Using 3D bioprinting, surgeons may make patient-specific organ models. By enabling them to visualize the patient's particular anatomy and perform the procedure beforehand, these models can aid them in planning complicated surgeries. This may result in surgeries that are more successful and accurate. Surgeons can produce tissue constructions from a patient's own cells using 3D bioprinting. The use of these constructions as grafts or replacements can help in tissue regeneration. In order to help surgeons better prepare for operation, 3D printing also enables medical personnel to create reference models from MRI and CT scans, which is driving the segment's revenue growth.

Moreover, strategic collaborations between major market companies and hospitals for the implementation of 3D printing for healthcare purposes is driving revenue growth of this segment.For instance, in Feburary 2021, Anatomiz3D Medtech and the Apollo Hospitals have worked collaboratively to design and construct hospital 3D printing facilities in India that would allow surgeons to visualize and manufacture implants for challenging surgical cases. The medical and surgical staff at Apollo Hospitals will collaborate with a multidisciplinary team made up of engineers and 3D designers in the hospital's 3D printing facilities. Thus, those mentioned elements aid in accelerating segment expansion.

Geographical Penetration

North America Accounted for Approximately 44.9% of the Market Share in 2022

The 3D bioprinting market is expanding in this region due to the increasing use of 3D bioprinting in hospitals for its features. The outstanding medical education and training programs in North America produce a workforce that is ready for implementing innovative technologies, such 3D bioprinting, in hospitals and clinics. Moreover, rising investments from companies and governmental entities, in addition to technological advancements in healthcare infrastructure are some factors helps to accelerate region growth.

For instance, in June 2023, In order to improve 3D bioprinting, 3D BioFibR, a Canadian tissue engineering company, has launched two new collagen fiber products: CollaFibR and CollaFibR 3D scaffold. The innovative, exclusive dry-spinning process developed by 3D BioFibR, which can produce collagen fibers at industrial scales, is used to make these new off-the-shelf products. According to details, these new products will provide significant benefits for applications involving tissue engineering and tissue culture. Thus, all of the above factors contribute to the region's growth.

Competitive Landscape

The major global players in the 3D bioprinting market Organovo Holdings Inc, UPM Biomedicals, GE Healthcare, Regemat 3D, 3DSMAN, CELLINK, Aspect Biosystem, Formlabs, Avay Biosciences, Precise Bio and others.

COVID-19 Impact Analysis

A variety of chronic disorders have been caused by the worldwide pandemic, aiding in the unexpected expansion of the 3D bioprinting companies. Healthcare professionals, the community, and the government face new challenges with each COVID-19 wave in terms of minimizing its impact and aftereffects. The last multiple waves encountered a problem with the shortage of COVID-19 test kits.

This significant issue was addressed by numerous 3D bioprinting companies, and test kits were produced in huge quantities. According to reports, Formlabs, one of the American businesses, produced 100,000 nose swabs for COVID-19 testing per day. Recently, a great number of pharmaceutical firms, R&D centers, and healthcare professionals have united to battle this terrible global pandemic in every way available.

By Component

  • 3D Bioprinters
  • Bioinks

By Technology

  • Extrusion-based bioprinting
  • Inkjet-based bioprinting
  • Pressure-assisted bioprinting
  • Laser-assisted bioprinting
  • Others

By Application

  • Medical

Tissue And Organ Generation

Medical Pills

Prosthetics And Implants

Others

  • Dental
  • Biosensors
  • Consumer/Personal Product Testing
  • Others

By End User

  • Hospitals
  • Research Organizations and Academic Institutes
  • Biopharmaceutical Companies

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

UK

France

Spain

Italy

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • In Feburary 2023, an new strategy for surgical operations requiring the reconstruction of human tissues has been developed by 3D Systems as a component of its tissue regeneration program. After making great strides in the creation of advanced bioprinting solutions for 3D printed solid organs, the company launched this program.
  • In March 2023, LabSkin and Chanel produce 3D bioprinted skin with spots. In order to advance its understanding of skin pigment spots, a key cosmetic problem among aging populations, particularly in Asia,. The luxury brand has successfully employed 3D bioprinting technologies to generate reconstructed human skin on which a dark spot can form in collaboration with LabSkin Creations.
  • In June 2022, the first multi-material, multi-fluidic bioprinting printhead, according to Finland-based bioprinting company Brinter, has been introduced. The digital multifluidic printing tool head is now undergoing pilot testing with a small number of customers. It was created for use with the company's own 3D bioprinters and geared toward pharmaceutical firms and research universities.

Why Purchase the Report?

  • To visualize the global 3D bioprinting market segmentation based on component, technology, application, end user and region as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of 3D bioprinting market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global 3D bioprinting market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Component
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The strategies followed by the companies
      • 4.1.1.2. Technological advancements in the treatment
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of the treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing demand of organ transplantation
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. Epidemiology Stats
  • 5.7. Pipeline Analysis
  • 5.8. Patent Analysis
  • 5.9. Technology Trend
  • 5.10. Russia-Ukraine War Impact Analysis
  • 5.11. SWOT Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 7.1.2. Market Attractiveness Index, By Component
  • 7.2. 3D Bioprinters *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 7.2.2.1. Medical Beds
      • 7.2.2.2. Bathroom & Toilet Assist Devices
      • 7.2.2.3. Reading, Writing & Computing Aids
    • 7.2.3. Bioinks

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. Extrusion-based bioprinting *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Inkjet-based bioprinting
  • 8.4. Pressure-assisted bioprinting
  • 8.5. Laser-assisted bioprinting
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Medical *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 9.2.2.1. Tissue And Organ Generation
      • 9.2.2.2. Medical Pills
      • 9.2.2.3. Prosthetics And Implants
      • 9.2.2.4. Others
  • 9.3. Dental
  • 9.4. Biosensors
  • 9.5. Consumer/Personal Product Testing
  • 9.6. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Research Organizations and Academic Institutes
  • 10.4. Biopharmaceutical Companies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Organovo Holdings Inc*
    • 13.1.1. Company Overview
    • 13.1.2. ProductPortfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. UPM Biomedicals
  • 13.3. GE Healthcare
  • 13.4. Regemat 3D
  • 13.5. 3DSMAN
  • 13.6. CELLINK
  • 13.7. Aspect Biosystem
  • 13.8. Formlabs
  • 13.9. Avay Biosciences
  • 13.10. Precise Bio.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us